This Article  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (108)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Journalology/ Peer Review/ Authorship  • Medical Practice  • Health Policy  • Medical Ethics  • Randomized Controlled Trial  • Alert me on articles by topic  Social Bookmarking   What's this?

A Statement From the International Committee of Medical Journal Editors

Catherine D. DeAngelis, MD, MPH; Jeffrey M. Drazen, MD; Frank A. Frizelle, MBChB, MMedSc, FRACS; Charlotte Haug, MD, PhD, MSc; John Hoey, MD; Richard Horton, FRCP; Sheldon Kotzin, MLS; Christine Laine, MD, MPH; Ana Marusic, MD, PhD; A. John P. M. Overbeke, MD, PhD; Torben V. Schroeder, MD, DMSc; Hal C. Sox, MD; Martin B. Van Der Weyden, MD

JAMA. 2004;292:1363-1364.

Altruism and trust lie at the heart of research on human subjects. Altruistic individuals volunteer for research because they trust that their participation will contribute to improved health for others and that researchers will minimize risks to participants. In return for the altruism and trust that make clinical research possible, the research enterprise has an obligation to conduct research ethically and to report it honestly. Honest reporting begins with revealing the existence of all clinical studies, even those that reflect unfavorably on a research sponsor's product.

Unfortunately, selective reporting of trials does occur, and it distorts the body of evidence available for clinical decision-making. Researchers (and journal editors) are generally most enthusiastic about the publication of trials that show either a large effect of a new treatment (positive trials) or equivalence of 2 approaches to treatment (noninferiority trials). Researchers (and journals) typically are less excited about trials that show that a new treatment is inferior to standard treatment (negative trials) and even less interested in trials that are neither clearly positive nor clearly negative, since inconclusive trials will not in themselves change practice. Irrespective of their scientific interest, trial results that place financial interests at risk are particularly likely to remain unpublished and hidden from public view. The interests of the sponsor or authors notwithstanding, anyone should be able to learn of any trial's existence and its important characteristics.

The case against selective reporting is particularly compelling for research that tests interventions that could enter mainstream clinical practice. Rather than a single trial, it is usually a body of evidence, consisting of many studies, that changes medical practice. When research sponsors or investigators conceal the presence of selected trials, these studies cannot influence the thinking of patients, clinicians, other researchers, and experts who write practice guidelines or decide on insurance-coverage policy. If all trials are registered in a public repository at their inception, every trial's existence is part of the public record, and the many stakeholders in clinical research can explore the full range of clinical evidence. We are far from this ideal at present, since trial registration is largely voluntary, registry data sets and public access to them varies, and registries contain only a small proportion of trials. In this Editorial, published simultaneously in all member journals, the International Committee of Medical Journal Editors (ICMJE) proposes comprehensive trials registration as a solution to the problem of selective awareness and announces that all 11 ICMJE member journals will adopt a trials-registration policy to promote this goal.

The ICMJE member journals will require, as a condition of consideration for publication, registration in a public trials registry. Trials must register at or before the onset of patient enrollment. This policy applies to any clinical trial starting enrollment after July 1, 2005. For trials that began enrollment prior to this date, the ICMJE member journals will require registration by September 13, 2005, before considering the trial for publication. We speak only for ourselves, but we encourage editors of other biomedical journals to adopt similar policies. For this purpose, the ICMJE defines a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (eg, phase 1 trials), would be exempt.

The ICMJE does not advocate one particular registry, but its member journals will require authors to register their trial in a registry that meets several criteria. The registry must be accessible to the public at no charge. It must be open to all prospective registrants and managed by a not-for-profit organization. There must be a mechanism to ensure the validity of the registration data, and the registry should be electronically searchable. An acceptable registry must include at minimum the following information: a unique identifying number, a statement of the intervention (or interventions) and comparison (or comparisons) studied, a statement of the study hypothesis, definitions of the primary and secondary outcome measures, eligibility criteria, key trial dates (registration date, anticipated or actual start date, anticipated or actual date of last follow-up, planned or actual date of closure to data entry, and date trial data are considered complete), target number of subjects, funding source, and contact information for the principal investigator. To our knowledge, at present, only www.clinicaltrials.gov,¹ sponsored by the United States National Library of Medicine, meets these requirements; there may be other registries, now or in the future, that meet all these requirements.

Registration is only part of the means to an end; that end is full transparency with respect to performance and reporting of clinical trials. Research sponsors may argue that public registration of clinical trials will result in unnecessary bureaucratic delays and destroy their competitive edge by allowing competitors full access to their research plans. We argue that enhanced public confidence in the research enterprise will compensate for the costs of full disclosure. Patients who volunteer to participate in clinical trials deserve to know that their contribution to improving human health will be available to inform health care decisions. The knowledge made possible by their collective altruism must be accessible to everyone. Required trial registration will advance this goal.

AUTHOR INFORMATION
Editorials represent the opinions of the authors and THE JOURNAL and not those of the American Medical Association.

Published online September 8, 2004 (doi:10.1001/jama.292.11.1363).

Author Affiliations: Dr DeAngelis is editor-in-chief, JAMA; Dr Drazen is editor-in-chief, New England Journal of Medicine; Prof Frizelle is editor, The New Zealand Medical Journal; Dr Haug is editor-in-chief, Norwegian Medical Journal; Dr Hoey is editor, CMAJ; Dr Horton is editor, The Lancet; Mr Kotzin is executive editor, MEDLINE; Dr Laine is senior deputy editor, Annals of Internal Medicine; Dr Marusic is editor, Croatian Medical Journal; Dr Overbeke is executive editor, Nederlands Tijdschrift voor Geneeskunde (Dutch Journal of Medicine); Dr Schroeder is editor, Journal of the Danish Medical Association; Dr Sox is editor, Annals of Internal Medicine; and Dr Van Der Weyden is editor, The Medical Journal of Australia.

REFERENCES
1. ClinicalTrials.gov Web site. Available at: http://www.clinicaltrials.gov. Accessed August 18, 2004.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED LETTERS

Clinical Trial Registration and the ICMJE
Rebecca Dresser
JAMA. 2005;293(2):157.
EXTRACT | FULL TEXT  

Clinical Trial Registration and the ICMJE
Omar Khalil, Rangaswamy Govindarajan, Mazin Safar, Laura Hutchins, and Paulette Mehta
JAMA. 2005;293(2):157.
EXTRACT | FULL TEXT  

Clinical Trial Registration and the ICMJE
Marc G. H. Besselink, Hein G. Gooszen, and Erik Buskens
JAMA. 2005;293(2):157-158.
EXTRACT | FULL TEXT  

Clinical Trial Registration and the ICMJE—Reply
Catherine D. DeAngelis
JAMA. 2005;293(2):158.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Trial Registration: A Great Idea Switches From Ignored to Irresistible
Drummond Rennie
JAMA. 2004;292(11):1359-1362.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Making information about clinical trials publicly available
Smyth
BMJ 2009;338:b2473-b2473.
FULL TEXT  

Promoting More Conservative Prescribing
Schiff and Galanter
JAMA 2009;301:865-867.
FULL TEXT  

Reporting clinical trial results
Pihlstrom
Journal of the American Dental Association 2009;140:12-15.
FULL TEXT  

Patient-Important Outcomes in Registered Diabetes Trials
Gandhi et al.
JAMA 2008;299:2543-2549.
ABSTRACT | FULL TEXT  

The Future of Clinical Trials Evaluating Blood Substitutes
Fergusson and McIntyre
JAMA 2008;299:2324-2326.
FULL TEXT  

Reporting Mortality Findings in Trials of Rofecoxib for Alzheimer Disease or Cognitive Impairment: A Case Study Based on Documents From Rofecoxib Litigation
Psaty and Kronmal
JAMA 2008;299:1813-1817.
ABSTRACT | FULL TEXT  

Impugning the Integrity of Medical Science: The Adverse Effects of Industry Influence
DeAngelis and Fontanarosa
JAMA 2008;299:1833-1835.
FULL TEXT  

Institutional Review Boards Should Require Clinical Trial Registration
Levin and Palmer
Arch Intern Med 2007;167:1576-1580.
FULL TEXT  

Issues in the Registration of Clinical Trials
Zarin et al.
JAMA 2007;297:2112-2120.
ABSTRACT | FULL TEXT  

Sex Differences in Perceived Risks, Distrust, and Willingness to Participate in Clinical Trials: A Randomized Study of Cardiovascular Prevention Trials
Ding et al.
Arch Intern Med 2007;167:905-912.
ABSTRACT | FULL TEXT  

Ethical Considerations in the Interpretation and Communication of Clinical Trial Results
Coultas
Proc Am Thorac Soc 2007;4:194-199.
ABSTRACT | FULL TEXT  

Clinical Response and Risk for Reported Suicidal Ideation and Suicide Attempts in Pediatric Antidepressant Treatment: A Meta-analysis of Randomized Controlled Trials
Bridge et al.
JAMA 2007;297:1683-1696.
ABSTRACT | FULL TEXT  

The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey
Ioannidis and Trikalinos
CMAJ 2007;176:1091-1096.
ABSTRACT | FULL TEXT  

Clinical Trial Registration Promotes Patient Protection and Benefit, Advances the Trust of Everyone, and Is Required
Irwin
Chest 2007;131:639-641.
FULL TEXT  

Registering a Clinical Trial in ClinicalTrials.gov
Zarin and Keselman
Chest 2007;131:909-912.
FULL TEXT  

Clinical trial registration at Tobacco Control
Bero
Tobacco Control 2006;15:417-418.
FULL TEXT  

The case of the misleading funnel plot
Lau et al.
BMJ 2006;333:597-600.
FULL TEXT  

Comparison of meeting abstracts and subsequent articles.
Fang and Huang
JAMA 2006;296:653-653.
FULL TEXT  

Clinical Trial Investigators and Their Prescribing Patterns: Another Dimension to the Relationship Between Physician Investigators and the Pharmaceutical Industry
Psaty and Rennie
JAMA 2006;295:2787-2790.
FULL TEXT  

Recent Trials in Hypertension: Compelling Science or Commercial Speech?
Psaty et al.
JAMA 2006;295:1704-1706.
FULL TEXT  

Insulin Therapy and In-Hospital Mortality in Critically Ill Patients: Systematic Review and Meta-analysis of Randomized Controlled Trials
Pittas et al.
JPEN J Parenter Enteral Nutr 2006;30:164-172.
ABSTRACT | FULL TEXT  

Instructions for Authors
JAMA 2006;295:103-111.
FULL TEXT  

ARVO Statement on Registering Clinical Trials
IOVS 2006;47:1-2.
FULL TEXT  

The Last of the 9th
Davidson
Diabetes Care 2006;29:168-169.
FULL TEXT  

Clinical Trials in Cardiovascular Medicine in an Era of Marginal Benefit, Bias, and Hyperbole
Loscalzo
Circulation 2005;112:3026-3029.
FULL TEXT  

Consensus and Controversy in Clinical Research Ethics
Brody et al.
JAMA 2005;294:1411-1414.
FULL TEXT  

Registration of Clinical Trials
Levin et al.
Arch Ophthalmol 2005;123:1263-1264.
FULL TEXT  

Optimizing the Science of Quality Improvement
Peterson
JAMA 2005;294:369-371.
FULL TEXT  

Reporting Conflicts of Interest, Financial Aspects of Research, and Role of Sponsors in Funded Studies
Fontanarosa et al.
JAMA 2005;294:110-111.
FULL TEXT  

Instructions for Authors
JAMA 2005;294:119-127.
FULL TEXT  

Clinical Trial Registration
Rosenberg
Arch Neurol 2005;62:1042-1042.
FULL TEXT  

Registration of Clinical Trials
Rivara
Arch Pediatr Adolesc Med 2005;159:685-685.
FULL TEXT  

Is This Clinical Trial Fully Registered?: A Statement From the International Committee of Medical Journal Editors
DeAngelis et al.
JAMA 2005;293:2927-2929.
FULL TEXT  

Letter Regarding Article by Armstrong et al, "Lessons Learned From a Clinical Trial"
Nessel et al.
Circulation 2005;111:e393-e393.
FULL TEXT  

Recent Developments in Health Law
J Law Med Ethics 2005;33:384-403.
 

Meeting our Ethical Obligations in Medical Publishing: Responsibilities of Editors, Authors, and Readers of Peer-Reviewed Journals
Albert et al.
Arch Ophthalmol 2005;123:684-686.
FULL TEXT  

Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1)
Krleza-Jeric et al.
BMJ 2005;330:956-958.
FULL TEXT  

Instructions for Authors
JAMA 2005;293:1788-1796.
FULL TEXT  

More on compulsory registration of clinical trials: GSK has created useful register
Krall and Rockhold
BMJ 2005;330:479-480.
FULL TEXT  

Instructions for Authors
Arch Otolaryngol Head Neck Surg 2005;131:185-185.
FULL TEXT  

Instructions for Authors
Arch Pediatr Adolesc Med 2005;159:197-197.
FULL TEXT  

Clinical Trial Registration and the ICMJE
Dresser
JAMA 2005;293:157-157.
FULL TEXT  

Clinical Trial Registration and the ICMJE
Khalil et al.
JAMA 2005;293:157-157.
FULL TEXT  

Clinical Trial Registration and the ICMJE
Besselink et al.
JAMA 2005;293:157-158.
FULL TEXT  

Trial Registration: Ignored to Irresistible
Krall and Rockhold
JAMA 2005;293:158-158.
FULL TEXT  

Instructions for Authors
JAMA 2005;293:108-115.
FULL TEXT  

Beginning Year 4
Coyle
Arch Gen Psychiatry 2005;62:14-14.
FULL TEXT  

Clinical Trial Registration: A Step Forward in Providing Transparency for the Positive and Negative Results of Clinical Trials
Callen and Robinson
Arch Dermatol 2005;141:75-75.
FULL TEXT  

Clinical Trial Registration to Be Required by Pediatrics
Lucey
Pediatrics 2005;115:177-177.
FULL TEXT  

The Ethical Conduct of Clinical Research Involving Critically Ill Patients in the United States and Canada: Principles and Recommendations
Am. J. Respir. Crit. Care Med. 2004;170:1375-1384.
FULL TEXT  

Trial Registration: A Great Idea Switches From Ignored to Irresistible
Rennie
JAMA 2004;292:1359-1362.
FULL TEXT